The first pharmaceutical company on the Science and Technology Innovation Board held a performance briefing, and it has been listed for less than three months

On March 1, it was reported that two companies including Dizhe Medicine took the lead and opened the 2021 performance briefing on the Science and Technology Innovation Board
.
At present, the number of companies on the Science and Technology Innovation Board has approached 400
.
The author noticed that Dizhe Medicine was listed on the Science and Technology Innovation Board on December 10, 2021, and it has been listed for less than three months so far
.
In addition, the company is also an unprofitable innovative drug company listed on the 5th set of listing standards on the Science and Technology Innovation Board
.
Due to the particularity of the company, investors have different standards for evaluating the value of Dizhe Pharmaceuticals and expressed their expectations for the company
.
On the evening of February 25, Dizhe Pharmaceutical disclosed its 2021 annual report.
The company's 2021 net profit accumulated a loss of 670 million yuan.
Compared with the net loss of 587 million yuan in the same period of the previous year, the loss further expanded
.
The company said that the main reason is to increase investment in clinical pipeline research and development
.
At present, Dizhe pharmaceutical products are still in the research and development stage and have not yet formed product sales
.
In 2021, Dizhe Pharmaceuticals has increased investment in research and development, with a year-on-year increase of 33.
7% in research and development, and a number of important clinical results have been achieved in the pipeline of products under development
.
Among them, the oral small-molecule targeted drug DZD9008 designed for known mutations in non-small cell lung cancer has initially verified its potential safety and efficacy in global phase I/II clinical trials
.
As of July 30, 2021, global clinical trial results show that DZD9008 has high target selectivity, good pharmacokinetic data, and excellent clinical efficacy
.
At present, DZD9008 has obtained the qualifications of "Breakthrough Therapy Drug Variety" in China and "Breakthrough Therapy" in the United States
.
The company said that after the product is certified, it is expected to pass the priority review to shorten the time for product listing review
.
It is understood that the number of patients with non-small cell lung cancer with EGFR exon 20 insertion mutation is huge in the world, and the number of patients is increasing.
Currently, there are 64,000 new patients in the world and 30,000 new patients in China.
These groups generally lack effective treatment.
means of treatment
.
If DZD9008 is successfully launched, it will bring new treatment options and hope to patients
.
In order to accelerate the clinical trial of DZD9008 against EGFR exon 20 insertion mutation in non-small cell lung cancer, and strive for DZD9008 to be approved for listing in major global markets as soon as possible to benefit patients, on February 26, the company also announced that it plans to conduct clinical trials including DZD9008 Some sub-projects of the new drug research and development project of the raised investment project and the amount of the raised funds are adjusted, and some of the over-raised funds of 39 million yuan are used to supplement the investment in the new drug project
.
After this adjustment, the investment amount of raised funds for new drug research and development projects will increase from 1,483.
42 million yuan to 1,522.
42 million yuan
.
Judging from the new drug research and development projects that are to be adjusted for the use of raised funds this time, the company plans to adjust the use of raised funds for DZD9008, including: First, it is planned to increase the use of DZD9008 for non-small cell lung cancer with EGFR exon 20 insertion mutation The related raised funds invested 450 million yuan in research and development, the investment in fundraising projects was adjusted to 600 million yuan, and the research and development stage was adjusted to the clinical research stage; second, the use of the raised funds for the combination drug for non-small cell lung cancer was adjusted to include EGFR exon 20.
R&D investment in the clinical R&D stage of the combination drug for non-small cell lung cancer including insertion mutations; thirdly, suspend the investment in clinical research of DZD9008 targeting EGFR exon 20 insertion mutation-positive other solid tumors, and accelerate the promotion of DZD9008 targeting EGFR 20 For non-small cell lung cancer with exon insertion mutation, the indications will be expanded in time according to the progress of the project
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.